Advertisement
Original Study| Volume 22, ISSUE 10, P2093-2099.e3, October 2021

Download started.

Ok

Disease Burdens of Alzheimer's Disease, Vascular Dementia, and Mild Cognitive Impairment

      Abstract

      Objectives

      Understanding disability-adjusted life-years (DALYs) based on dementia subtypes and mild cognitive impairment (MCI) is essential for optimal resource allocation. This study aimed to investigate disease burdens of various dementias and MCI in a representative South Korean population.

      Design

      Retrospective cohort study.

      Setting and Participants

      6481 Korean older adults.

      Methods

      We estimated the disease-specific DALYs.

      Results

      DALYs due to MCI and all-cause dementia are estimated to increase from 1295 per 100,000 in 2016 to 9501 per 100,000 in 2065. In 2016, DALYs attributed to Alzheimer's dementia, vascular dementia, and MCI accounted for 33% (423 per 100,000), 20% (316 per 100,000), and 24% (123 per 100,000), respectively, of the total DALYs due to MCI and all-cause dementia. In 2065, DALYs due to Alzheimer's dementia, vascular dementia, and MCI will account for 38% (3654 per 100,000), 17% (1654 per 100,000), and 27% (2585 per 100,000) of total DALYs due to MCI and all-cause dementia, respectively.
      The years of life lived with disability (YLDs) due to MCI and all-cause dementia are estimated to rise from 479 per 100,000 in 2016 to 2807 per 100,000 in 2065. In 2016, YLDs due to Alzheimer's dementia, vascular dementia, and MCI composed 37% (177 per 100,000), 18% (85 per 100,000), and 15% (70 per 100,000), respectively, of the total YLDs due to MCI and all-cause dementia. In 2065, YLDs due to Alzheimer's dementia, vascular dementia, and MCI will account for 48% (1358 per 100,000), 15% (410 per 100,000), and 10% (290 per 100,000), respectively, of total YLDs due to MCI and all-cause dementia.

      Conclusions and Implications

      Considering the rapidly growing disease burden, resources should be allocated to continuously monitor and manage the MCI and dementia burden. Particular attention to Alzheimer's dementia is required considering its significant contribution to current and future disease burden, especially to YLD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mathers C.
        • Boschi-Pinto C.
        Global Burden of Disease Global Program on Evidence for Health Policy.
        World Health Organization, Geneva2000
        • Global Burden of Disease Study Collaborators
        Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: A systematic analysis for the global burden of disease study 2016.
        Lancet Neurol. 2019; 18: 88-106
        • Kim K.W.
        • Park J.H.
        • Kim M.H.
        • et al.
        A nationwide survey on the prevalence of dementia and mild cognitive impairment in South Korea.
        J Alzheimers Dis. 2011; 23: 281-291
        • Onandia-Hinchado I.
        • Diaz-Orueta U.
        Health related quality of life in individuals with cognitive decline and discrepancies between patients and their proxies.
        Arch Gerontol Geriat. 2019; : 85
        • Bonfiglio V.
        • Umegaki H.
        • Kuzuya M.
        Quality of life in cognitively impaired older adults.
        Geriatr Gerontol Int. 2019; 19: 999-1005
        • Salomon J.A.
        • Haagsma J.A.
        • Davis A.
        • et al.
        Disability weights for the global burden of disease 2013 study.
        Lancet Glob Health. 2015; 3: e712-e723
        • Han J.W.
        • Kim T.H.
        • Kwak K.P.
        • et al.
        Overview of the Korean longitudinal study on cognitive aging and dementia.
        Psychiatry Investig. 2018; 15: 767-774
        • Lee J.H.
        • Lee K.U.
        • Lee D.Y.
        • et al.
        Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease assessment packet (CERAD-K): Clinical and neuropsychological assessment batteries.
        J Gerontol B Psychol. 2002; 57: P47-P53
        • Rosen W.G.
        • Terry R.D.
        • Fuld P.A.
        • et al.
        Pathological verification of ischemic score in differentiation of dementias.
        Ann Neurol. 1980; 7: 486-488
        • Sherbourne C.D.
        • Stewart A.L.
        The MOS social support survey.
        Soc Sci Med. 1991; 32: 705-714
        • Miller M.D.
        • Paradis C.F.
        • Houck P.R.
        • et al.
        Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale.
        Psychiatry Res. 1992; 41: 237-248
        • Buysse D.J.
        • Reynolds 3rd, C.F.
        • Monk T.H.
        • et al.
        The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research.
        Psychiatry Res. 1989; 28: 193-213
        • Lee D.Y.
        • Lee K.U.
        • Lee J.H.
        • et al.
        A normative study of the CERAD neuropsychological assessment battery in the Korean elderly.
        J Int Neuropsych Soc. 2004; 10: 72-81
        • McKhann G.
        • Drachman D.
        • Folstein M.
        • et al.
        Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease.
        Neurology. 1984; 34: 939-944
        • Roman G.C.
        • Tatemichi T.K.
        • Erkinjuntti T.
        • et al.
        Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.
        Neurology. 1993; 43: 250-260
        • McKeith I.G.
        • Galasko D.
        • Kosaka K.
        • et al.
        Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop.
        Neurology. 1996; 47: 1113-1124
        • Neary D.
        • Snowden J.S.
        • Gustafson L.
        • et al.
        Frontotemporal lobar degeneration—A consensus on clinical diagnostic criteria.
        Neurology. 1998; 51: 1546-1554
        • Oslin D.
        • Atkinson R.M.
        • Smith D.M.
        • et al.
        Alcohol related dementia: Proposed clinical criteria.
        Int J Geriatr Psych. 1998; 13: 203-212
        • Petersen R.C.
        Mild cognitive impairment as a diagnostic entity.
        J Intern Med. 2004; 256: 183-194
        • Rabin R.
        • de Charro F.
        EQ-5D: a measure of health status from the EuroQol group.
        Ann Med. 2001; 33: 337-343
        • Williams A.
        EuroQol—A new facility for the measurement of health-related quality-of-life.
        Health Policy. 1990; 16: 199-208
        • Lee Y.K.
        • Nam H.S.
        • Chuang L.H.
        • et al.
        South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states.
        Value Health. 2009; 12: 1187-1193
        • Kim K.W.
        • Park J.H.
        • Kim M-.H.
        • Kim M-.D.
        Nationwide survey on the prevalence of dementia in Korean elders. Ministry of Health & Welfare, Korea2009
        • Barendregt J.J.
        • Van Oortmarssen G.J.
        • Vos T.
        • et al.
        A generic model for the assessment of disease epidemiology: the computational basis of DisMod II.
        Popul Health Metr. 2003; 1: 4
        • Murray C.J.L.
        • Lopez A.D.
        Injuries and Risk Factors in 1990 and Projected to 2020.
        The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases. Harvard University Press, Cambridge, MA1996
        • Department of Information, Evidence and Research, WHO
        WHO Methods and Data Sources for Global Burden of Disease Estimates 2000-2015.
        World Health Organization, Geneva2017
        • Yoon J.
        • Oh I.H.
        • Seo H.
        • et al.
        Disability-adjusted life years for 313 diseases and injuries: The 2012 Korean Burden of Disease Study.
        J Korean Med Sci. 2016; 31: S146-S157
        • Park B.
        • Park B.
        • Han H.
        • et al.
        Projection of the years of life lost, years lived with disability, and disability-adjusted life years in Korea for 2030.
        J Korean Med Sci. 2019; 34: e92
        • Kim K.W.
        Global treands of dementia policy. National Institutes of Dementia, Korea2019
        • Institute for Health Metrics and Evaluation
        Global Health Data Exchange.
        (Available at:)
        https://vizhub.healthdata.org/gbd-compare/
        Date: 2016
        Date accessed: February 6, 2019
        • Salomon J.A.
        • Vos T.
        • Hogan D.R.
        • et al.
        Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010 (vol 380, pg 2129, 2012).
        Lancet. 2013; 381: 628
        • Haywood K.L.
        • Garratt A.M.
        • Fitzpatrick R.
        Quality of life in older people: A structured review of generic self-assessed health instruments.
        Qual Life Res. 2005; 14: 1651-1668
        • Ankri J.
        • Beaufils B.
        • Novella J.L.
        • et al.
        Use of the EQ-5D among patients suffering from dementia.
        J Clin Epidemiol. 2003; 56: 1055-1063
        • Coucill W.
        • Bryan S.
        • Bentham P.
        • et al.
        EQ-5D in patients with dementia: An investigation of inter-rater agreement.
        Med Care. 2001; 39: 760-771
        • Orgeta V.
        • Edwards R.T.
        • Hounsome B.
        • et al.
        The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers.
        Qual Life Res. 2015; 24: 315-324
        • Hounsome N.
        • Orrell M.
        • Edwards R.T.
        EQ-5D as a quality of life measure in people with dementia and their carers: Evidence and key issues.
        Value Health. 2011; 14: 390-399